Retrospective cohort study assesses disease severity outcomes of extended dupilumab dosing in atopic dermatitis, suggesting potential benefits for patients.
Dupilumab is effective for moderate‐to‐severe atopic dermatitis, but optimal long‐term dosing is unclear. In this single‐centre retrospective study, 49 patients underwent dose extension to 300 mg Q3W or 300 mg Q4W, with EASI scores remaining low and stable over 18 months. Patients extending for good disease control had higher EASI90 rates. The impact of age, disease severity and therapy duration remains uncertain.
No takes yet. Share an insight, caveat, or question.
McClatchy et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: